Synthesis, Ti(IV) intake by apotransferrin and cytotoxic properties of functionalized titanocene dichlorides.
Functionalization of cyclopentadienyl (Cp) ligands and incorporation of these into a Ti(IV) center require careful design and selection of the appropriate synthetic routes to obtain the desired product in reasonably good yields. As part of our research efforts in the area of titanocene antitumor agents, we have revisited the synthesis of Cp rings with electron-withdrawing groups and their corresponding titanocene dichlorides, (Cp-R)(2)TiCl(2) and (Cp-R)CpTiCl(2), where R is CO(2)CH(3) and CO(2)CH(2)CH(3). These complexes were characterized by elemental analysis and (1)H and (13)C NMR and IR spectroscopies. This report presents the first detailed synthetic route for (Cp-CO(2)CH(2)CH(3))CpTiCl(2) and provides an alternate route for synthesis of (Cp-R)(2)TiCl(2) complexes. The ability of these complexes to deliver Ti(IV) to apotransferrin was investigated to elucidate how the functionalized Cp ligands affect the titanium intake by apotransferrin. The subject complexes transfer Ti(IV) to human apotransferrin, loading both N- and C-lobes. The antitumor activity of these complexes against HT-29 cancer colon cells was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Carboethoxy Cp functionalization results in complexes with a toxicity comparable to that of titanocene dichloride. The carbomethoxy-functionalized complexes proved to be nonactive at the time intervals studied here, regardless of their ability to donate the titanium atom to human apotransferrin.
Gao
Li Ming
LM
Department of Chemistry, University of Puerto Rico, Mayaguez 00681, Puerto Rico.
Hernández
Ramón
R
Matta
Jaime
J
Meléndez
Enrique
E
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D001059:Apoproteins / Q000737:chemistry*; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008956:Models, Chemical; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D013057:Spectrum Analysis; D014168:Transferrin / Q000737:chemistry*
D000970:Antineoplastic Agents; D001059:Apoproteins; D008024:Ligands; D009942:Organometallic Compounds; D014168:Transferrin; C028284:apotransferrin; C020528:titanocene dichloride